Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

337
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
337
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

183
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
183
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

158
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
158
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

840
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
840
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.5K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.5K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

493
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
493

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End-of-Life Education in a Prelicensure Nursing Program.

Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association·2024
Same author

First Oral Treatment Specific for Postpartum Depression.

Nursing for women's health·2024
Same author

Sustaining the collaborative chronic care model in outpatient mental health: a matrixed multiple case study.

Implementation science : IS·2024
Same author

Adaptation for sustainability in an implementation trial of team-based collaborative care.

Implementation research and practice·2024
Same author

Interdisciplinary behavioral health provider perceptions of implementing the Collaborative Chronic Care Model: an i-PARIHS-guided qualitative study.

Implementation science communications·2023
Same author

Feasibility of Group-Based Implementation Facilitation for Video Telemental Health.

Journal of technology in behavioral science·2023

Related Experiment Video

Updated: Dec 9, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.0K

Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.

Kendra Weaver, Kelley Stallworth, Kala K Blakely

    Nursing for Women'S Health
    |September 5, 2020
    PubMed
    Summary

    Cefiderocol, a novel cephalosporin antibiotic, offers a new treatment for complicated urinary tract infections in adults with limited options due to resistant bacteria. It is administered intravenously and may cause gastrointestinal side effects.

    Keywords:
    FetrojaGram-negativeUTIantibiotic resistancecefiderocolcephalosporincomplicated urinary tract infectionmultidrug-resistant organisms

    More Related Videos

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    5.2K
    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.2K

    Related Experiment Videos

    Last Updated: Dec 9, 2025

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
    06:51

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

    Published on: December 10, 2016

    13.0K
    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
    11:15

    Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

    Published on: July 24, 2021

    5.2K
    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.2K

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Urology

    Background:

    • Complicated urinary tract infections (cUTIs) pose a significant challenge due to rising antibiotic resistance.
    • Limited effective treatment options exist for cUTIs caused by multidrug-resistant Gram-negative bacteria.
    • Cefiderocol represents a new class of cephalosporin antibiotic.

    Purpose of the Study:

    • To introduce cefiderocol as a new treatment option for complicated urinary tract infections (cUTIs).
    • To outline the indications, dosage, and administration of cefiderocol.
    • To report common adverse events associated with cefiderocol therapy.

    Main Methods:

    • Review of the U.S. Food and Drug Administration (FDA) approval of cefiderocol in 2019.
    • Description of cefiderocol's spectrum of activity against key uropathogens.
    • Information on recommended dosage and adjustments based on renal function.

    Main Results:

    • Cefiderocol is approved for adults (≥18 years) with cUTIs caused by specific resistant bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
    • The standard dose is 2g intravenously every 8 hours, infused over 3 hours.
    • Dose adjustments are necessary for patients with creatinine clearance outside the 60–120 mL/min range.

    Conclusions:

    • Cefiderocol provides a valuable new therapeutic option for patients with difficult-to-treat cUTIs.
    • Understanding cefiderocol's dosing and potential adverse effects, such as gastrointestinal symptoms, is crucial for effective clinical use.
    • This antibiotic addresses a critical unmet need in managing infections caused by resistant pathogens.